Psychopharmacology and Psychiatry Updates
von Psychopharmacology Institute
- wöchentlichErscheinungsrhythmus
- 13 mintypische Länge
- vor 3 Tagenletzte Folge
Folgenzu den neuesten
Monthly Injections, Long-Term Recovery: Naltrexone for OUD
In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation per
Antipsychotics and Aspiration Risk
In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in
Buprenorphine, Methadone, and Naltrexone: Helping Patients with OUD Decide
In this episode, we explore how to choose between methadone, buprenorphine, and naltrexone for opioid use disorder treatment. With over 100,000 overdose deaths annually, how do we match the right medication to save each patient's life? Facu
Managing OUD with Buprenorphine: Clinical Pearls
In this episode, we explore buprenorphine management for opioid use disorder, covering induction protocols, dosing strategies, and long-term maintenance. Why do patients need to be in withdrawal before starting this life-saving medication,
Valproate Weight Gain: Do Lower Doses Help?
In this episode, we explore groundbreaking research on valproate's dose-dependent weight gain effects. Could prescribing lower doses be the key to maintaining therapeutic benefits while minimizing one of psychiatry's most challenging side e
Methadone for Opioid Use Disorder
In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness,
Clozapine and Compulsions: New Research On An Old Side Effect
In this episode, we explore the puzzling connection between clozapine and obsessive-compulsive symptoms in schizophrenia patients. Does this wonder drug actually cause OCD, or are we missing a deeper story about how protective behaviors tra
Naltrexone vs. Topiramate: FDA-Approved vs. Off-Label Options for MAUD
In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-appr
Beyond Tapering: Supporting Patients Through Benzodiazepine Discontinuation
In this episode, we discuss the critical challenges of benzodiazepine discontinuation, exploring Benzodiazepine-Induced Neurological Dysfunction (BIND) and effective support strategies for patients experiencing protracted withdrawal. What c
Beyond Blood Counts: Clozapine, Bowel Obstruction, and Pneumonia
In this episode, we explore the potentially fatal side effects of clozapine that often receive less attention than agranulocytosis: bowel obstruction and pneumonia. Could your vigilant monitoring of blood counts be overshadowing equally dan
